Pfizer may seem like a poor investment, despite its recently very low forward-looking price-to-earnings (P/E) ratio below 9; ...

Pfizer (NYSE:PFE) shares are finally starting to attract attention after gaining close to 7% in a single trading session on ...

Pfizer's stock price is down materially from its 2021 highs, but it is also up notably from its April 2025 lows.

Pfizer's 7% dividend yield ranks among the highest in the healthcare sector, nearly triple the average of the S&P 500. The payout ratio has improved to 89% from over 100% in recent quarters, but ...

Pfizer's payout ratio is around 90% of earnings, which is high for a dividend stock. It reported strong operational growth of 10% in its most recent quarter. The company continues to focus on cutting ...

Dividend stocks can be great income-producing investments, but chasing high yields can sometimes leave you exposed to ...

Let's start with one of my favorite ultra-high-yielders, Ares Capital (NASDAQ: ARCC). This stock pays a forward dividend ...

Pfizer acquires Metsera to enter the booming obesity drug market with next-gen GLP-1 therapies. Find out why PFE stock is a hold.

Pfizer has an attractive 7.2% dividend yield, but there are some pros and cons you need to understand before you buy it.

This week we saw the Pfizer Inc. (NYSE:PFE) share price climb by 15%. But that cannot eclipse the less-than-impressive ...

Pfizer (NYSE: PFE) has become the dividend investor's siren song. With shares down 31% over the past five years and a current yield of 7%, the pharmaceutical giant offers one of the juiciest payouts ...